Live feed
Filing
SCHEDULE 13D
SCHEDULE 13D0001231919-26-000070·Aktis Oncology, Inc.
Schedule 13D ownership disclosure
AKOUSTIS TECHNOLOGIES INC
Common Stock · CUSIP: 00973N102
Event date: 2026-01-12
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- MPM BIOVENTURES 2018, L.P.Reported CIK 0001729505
Shares: 3,950,528.00 · Class: 7.4%
- MPM BIOVENTURES 2018 (B), L.P.Reported CIK 0001729504
Shares: 206,964.00 · Class: 0.4%
- MPM BioVentures 2018 GP LLCReported CIK 0001818701
Shares: 4,157,492.00 · Class: 7.8%
- MPM ASSET MANAGEMENT INVESTORS BV2018 LLCReported CIK 0001734817
Shares: 77,911.00 · Class: 0.1%
- MPM BioVentures 2018 LLCReported CIK 0001818702
Shares: 4,235,403.00 · Class: 7.9%
- MPM ONCOLOGY INNOVATIONS FUND LPReported CIK 0001719960
Shares: 847,080.00 · Class: 1.6%
- MPM Oncology Innovations Fund GP LLCReported CIK 0001857903
Shares: 847,080.00 · Class: 1.6%
- Oncology Impact Private Investment Fund 2, L.P.Reported CIK 0002104306
Shares: 4,835,872.00 · Class: 9.1%
- MPM Oncology Investments 2 LLC
Shares: 4,835,872.00 · Class: 9.1%
- MPM ASSET MANAGEMENT LLCReported CIK 0001263048
Shares: 341,709.00 · Class: 0.6%
- ANSBERT GADICKEReported CIK 0001134655
Shares: 10,260,064.00 · Class: 19.3%
- LUKE EVNINReported CIK 0001134657
Shares: 5,082,483.00 · Class: 9.5%
- Todd FoleyReported CIK 0001473930
Shares: 4,237,506.00 · Class: 8.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001231919-26-000070
- Form type
- SCHEDULE 13D
- Filer
- Aktis Oncology, Inc.
- CIK
- CIK 2035832
- Filed
- Jan 20, 2026
- Reporting period
- Jan 12, 2026
- Description
- Schedule 13D beneficial ownership